Our group
An independent Group committed to therapeutic progress to serve patient needs.
35th
LARGEST PHARMACEUTICAL
GROUP WORLDWIDE
and 2nd largest pharmaceutical
Group in France*.
Close to 140
COUNTRIES in which the
Group’s medicines are distributed
Over 22
THOUSAND EMPLOYEES worldwide
*IQVIA, Analytics Link / World 76 countries – MAT Q1-2024
Servier, a global pharmaceutical group
Servier is a global pharmaceutical group governed by a nonprofit foundation, committed to making a meaningful social impact for patients and contributing to a sustainable world.
The Group’s unique governance model ensures its independence while fostering long-term innovation, with 100% of its profits reinvested in the company’s development.
As a world leader in cardiometabolism and venous diseases, Servier drives transformative innovation in chronic conditions through a holistic approach, making patient adherence a priority across the globe. Its ambition is to become a leading player in rare cancers, which is why the Group invests heavily in oncology, allocating close to 70% of its R&D budget to this field. By leveraging precision medicine, Servier develops therapies that are more targeted and more effective.
Bolstered by its success in oncology, Servier has expanded into neurology, a key driver of future growth. The Group focuses on a select number of neurodegenerative diseases, where accurate patient profiling enables targeted therapeutic responses through precision medicine. To further enhance access to high-quality, affordable care, Servier also provides an extensive range of generic medicines, building on well-established brands in France, Eastern Europe, and Brazil. In all its activities and at every stage of the medicine life cycle, the Group integrates the patient’s voice.
Headquartered in France, Servier operates in close to 140 countries. In 2023-2024, the Group, which employs over 22,000 people worldwide, achieved sales revenue of €5.9 billion.
Our vocation
We are committed to therapeutic progress to serve patient needs.
Our values
Date to innovate
Care
Grow by sharing
Commit to succeed
Our vision
Founded to serve health, our Group aspires to make a meaningful social impact for patients and for a sustainable world.
A comprehensive healthcare offering
Every day, Servier helps to treat patients in close to 140 countries using its extensive range of brand-name and generic medicines. In line with our conviction to offer a comprehensive range of health care solutions, we also provide e-health solutions that cover the entire patient journey.
Servier brand-name medicines
GENERIC MEDICINES
Research & Innovation
Our aim is clear—to pick up the pace of research and efforts to develop new therapeutic solutions guided by a long-term vision.
Day in, day out, our teams work tirelessly to discover and develop medicines where patient needs are greatest.
Servier’s governance model headed by a non-profit foundation aligns perfectly with the long-term perspective required for research and development. Our independence from market forces means we can invest heavily in R&D to innovate and develop new medicines.
That is why we invest close to 20% of our sales revenue (excl. generic medicines) each year in R&D.
Servier research & development institute in Paris-Saclay
In Paris-Saclay, Servier will be able to develop a more agile and open approach to R&D that centers even more closely around the patient to speed up the discovery of innovative therapeutic solutions.
- 2023 opening in 2023
- 45,000sqm a building spanning
- 1,500 employees
A partner of choice
Our partnership strategy centers around a single objective to ramp up the speed with which we develop treatments that significantly improve patients’ quality of life. We take a people-oriented approach to our partnerships, and we focus on creating win-win situations by pooling our expertise.
We are keen to invest in innovation that benefits patients in the future.
A strong industrial network
At our 14 production sites located throughout the world, we produce and distribute our medicines to the highest standards on quality, safety and reliability.
By harnessing digital innovation across the entire value chain, we continue to enhance our agility to meet patient demand.
Making a positive impact on society
The Group has adopted a proactive approach to Corporate Social Responsibility. This approach is structured around 4 CSR commitments that bring together 17 priority challenges, identified using a diagnosis based on ISO 26000 guidelines and interviews with stakeholders.
Since 2016, the Mécénat Servier Charity Fund has been supporting general interest initiatives in France and abroad in the fields of health care, education and community life. More information: https://mecenat.servier.com/